FDA to set opioid limits in poppy seeds after 19 U.S. deaths

What it does

This bill directs the FDA to establish and enforce contamination limits for morphine, codeine, and other alkaloid compounds in poppy seeds sold in the U.S., treating poppy seeds that exceed those limits as adulterated food prohibited from interstate commerce. The bill is named after Stephen Hacala, a 24-year-old who died from morphine poisoning caused by contaminated poppy seeds, and cites at least 19 confirmed U.S. deaths from the same cause, plus documented cases of women testing positive for opiates at childbirth and military personnel at risk of failed drug tests.

Why we flagged it

The bill's operative mechanism is a straightforward public-health mandate: the FDA must set contamination limits for opioid alkaloids in poppy seeds and treat exceedances as food adulteration. This is classic food-safety regulation, not a market intervention or industry carve-out.

What the text implies

• The bill does not specify what contamination thresholds the FDA must set; the agency has discretion to define 'unsafe' within the 1-year rulemaking window. If thresholds are set too high, the public-health benefit may be minimal; if set too low, legitimate poppy seed imports and domestic use may be disrupted.
• Poppy seeds are a common culinary ingredient in many cuisines and baked goods. A strict contamination standard could reduce availability or increase prices for consumers who use poppy seeds in cooking, though this is a minor trade-off against the documented mortality risk.
• The bill preserves DEA authority to regulate contaminated poppy seeds as controlled substances under the Controlled Substances Act, creating potential dual-track enforcement (FDA food adulteration + DEA drug control). Coordination between agencies will be necessary to avoid gaps or conflicts.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain a direct public-health protection: the FDA will establish science-based limits on opioid contamination in a food product that has caused documented deaths and unintended opioid exposure (including in newborns and military personnel). The bill imposes no new costs on consumers—it simply prevents a known hazard from being sold.

Named in the bill

Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Department of Defense (DoD), Drug Enforcement Administration (DEA), Federal Food, Drug, and Cosmetic Act (FDCA), Controlled Substances Act (CSA)

Where it stands

5 cosponsors: 3 Republicans, 2 Democrats.

• Apr 2, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 2, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $30,000 in lobbying spend. A filing names 27 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Steve Womack, the sponsor, reported $925,850 in PAC receipts in the 2026 cycle.

• Mondelez International, Inc. — $30,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.